Earlier this week, Optalysys CEO, Dr Nick New, spoke to MIT Technology Review about how optical processing technology could transform genomics. Optalysys is currently building an optical co-processor product for the bioinformatics market through a collaboration project (Project GENESYS) with the Earlham Institute (formerly The Genome Analysis Centre). In the article, Dr New also describes why now is the right time for optical processing technology to come to market and covers some of the other focus areas where Optalysys is applying their technology.
Optalysys was founded in 2013. CEO Dr Nick New, a renowned world expert in optical pattern recognition, developed the forerunner to the Optalysys technology whilst carrying out his PhD on optical pattern recognition at Cambridge University. Dr New went on to forge relationships with international academic and commercial institutions before securing funding to take Optalysys forward.
The Optalysys team includes specialists in software development, Computational Fluid Dynamics (CFD), free-space optics, optical engineering and production engineering.
The company has several patents covering its groundbreaking technology.